EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cabaletta Bio's enterprise value is $262.18 Mil.
Cabaletta Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Cabaletta Bio's EV-to-Revenue for today is .
The historical rank and industry rank for Cabaletta Bio's EV-to-Revenue or its related term are showing as below:
CABA's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.775 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-04-30), Cabaletta Bio's stock price is $10.35.
Cabaletta Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Cabaletta Bio's PS Ratio for today is .
Cabaletta Bio EV-to-Revenue Historical Data
The historical data trend for Cabaletta Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cabaletta Bio's EV-to-Revenue
For the Biotechnology subindustry, Cabaletta Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cabaletta Bio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cabaletta Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cabaletta Bio's EV-to-Revenue falls into.
Cabaletta Bio's current Enterprise Value is $262.18 Mil.
Cabaletta Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cabaletta Bio (NAS:CABA) EV-to-Revenue Explanation
Cabaletta Bio's share price for today is $10.35.
Cabaletta Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cabaletta Bio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Cabaletta Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Cabaletta Bio (Cabaletta Bio) Business Description
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CABA has been successfully added to your 